RIPK1 and ovarian carcinoma: However, RIPK1 KO attenuated the cytotoxic effect of cisplatin in vitro and in vivo, demonstrating the dual role of RIPK1 in ovarian cancer, acting as a tumor-promoting factor to maintain cancer cell proliferation or as a tumor-suppressing factor to facilitate the anticancer activity of cisplatin by the regulation of both apoptosis and necroptosis [30].